Metraipolis › archive › dc_79637feeee9c
Loss of STAT6 leads to anchorage-independent growth and trastuzumab resistance in HER2+ breast cancer cells — Europe PMC PMID:32525891
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/32525891
- DOI
- 10.1371/journal.pone.0234146
- License (as archived)
- CC0-1.0
- Archived
- 2026-11-08T12:24:28.802Z
- SHA-256 of the archived text
4f1970f02c28810ca3f2bd10fc046dc03e77b19e6ba9a0ae79e015a285c52ba8- Stable URL of this page
https://metraipolis.com/documento/dc_79637feeee9c
How to cite
Loss of STAT6 leads to anchorage-independent growth and trastuzumab resistance in HER2+ breast cancer cells — Europe PMC PMID:32525891 — Europe PMC (en), https://europepmc.org/article/MED/32525891 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_79637feeee9c (Metraipolis archive dc_79637feeee9c, sha256 4f1970f02c28810ca3f2bd10fc046dc03e77b19e6ba9a0ae79e015a285c52ba8)
BibTeX
@misc{dc79637feeee9c,
title = {Loss of STAT6 leads to anchorage-independent growth and trastuzumab resistance in HER2+ breast cancer cells — Europe PMC PMID:32525891},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/32525891},
note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_79637feeee9c; sha256 4f1970f02c28810ca3f2bd10fc046dc03e77b19e6ba9a0ae79e015a285c52ba8},
year = {2026}
}Archived text
Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/32525891. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
Approximately 20% of breast cancers are HER2-positive. Trastuzumab has improved patient outcomes significantly for these cancers. However, acquired resistance remains a major hurdle in the clinical management of these patients. Therefore, identifying molecular changes that cause trastuzumab resistance is worthwhile. STAT6 is a transcription factor that regulates a variety of genes involved in cell cycle regulation, growth inhibition, and apoptosis. STAT6 expression is lost in approximately 3% of breast cancers, but little work has been done in the context of trastuzumab resistance in breast cancer. In isogenic cell line pairs, we observed that trastuzumab-resistant cells expressed significantly lower levels of STAT6 compared to trastuzumab-sensitive cells. Therefore, in order to study the consequences of STAT6 loss in HER2+ breast cancer, we knocked out both alleles of the STAT6 gene using somatic cell gene targeting. Interestingly, loss of STAT6 resulted in anchorage-independent growth and changes in several genes involved in epithelial to mesenchymal transition. This study suggests that STAT6 may play a role in the pathophysiology of HER2+ human breast cancer. Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera). Pubblicazione: PloS one, 2020 (prima pubblicazione 2020-06-11). Identificativi: PMID 32525891 · PMCID PMC7289443 · DOI 10.1371/journal.pone.0234146. Pagina: https://europepmc.org/article/MED/32525891 — https://doi.org/10.1371/journal.pone.0234146. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito). Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0. Letto il 2026-11-08T12:20:12.317Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.